Tofacitinib Effective in Refractory Still's Disease
Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in…
View Resource
Systemic JIA-Associated Lung Disease
A disease you’ve never heard of is becoming increasingly common and carries a very…
View Resource
Autoinflammatory Diseases at the ACR Annual Meeting
It has been a wonderful year for autoinflammatory diseases at the ACR Annual Meeting.…
View Resource
Increasing Lung Disease in Systemic JIA
A single-center cohort analysis shows that lung disease (LD) is increasingly seen in children…
View Resource
First Line IL-1 Inhibition in Systemic JIA
First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective…
View Resource
Impressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
The drug retention rate of interleukin-1 inhibitors (IL-1) used to treat systemic juvenile idiopathic…
View Resource
Genetic Diagnosis for Previously Undiagnosed Disorders
The NEJM has reported the NIH’s Undiagnosed Diseases Network (UDN) study results of genetically…
View Resource
IL-6 for Adult Still's: A New Option?
Some clinical benefits were seen among patients with adult-onset Still’s disease treated with tocilizumab…
View Resource
Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in…
View Resource
Genetic Breakthrough in Systemic JIA
The identification of a genetic susceptibility locus for systemic juvenile idiopathic arthritis (sJIA) has…
View Resource